An experimental AIDS vaccine of Merck & Co. has exceeded expectations and led to a double enrollment in the trial to 3,000, researchers said.
The trial, conducted in healthy volunteers to determine their immune response to the vaccine, might indicate whether the immune reactions could prevent or control AIDS, reported the Wall Street Journal Friday.
The vaccine, called MRKAd5, uses an adenovirus -- a common-cold virus -- as a missile armed with man-made copies of three AIDS virus genes, has resulted in a stronger-than-expected immune response.
MRKAd5 has boosted such killer T-cells, which seek and destroy human cells infected by HIV by 50-fold to 100-fold -- an immune reaction comparable with successful vaccines for diseases like smallpox or measles, according to Lawrence Corey, principal investigator of the HIV Vaccine Trials Network in Seattle.
However, the vaccine doesn't elicit antibodies, another key element of immune protection.
Copyright 2005 by United Press International
Related stories:
Viral recombination another way HIV fools the immune system
When individuals infected with HIV become infected with a second strain of the virus, the two viral strains can exchange genetic information, creating a third, recombinant strain of the virus. It is known that the presence of multiple viral strains, called superinfection, frequently leads to a loss of immune control of viral levels. Now a study from the Partners AIDS Research Center at Massachusetts General Hospital (PARC/MGH) shows that how and where viral strains swap DNA may be determined by the immune response against the original infecting strain. Their report will appear in the
Journal of Experimental Medicine and has been released online.
HIV conquers immune system faster than previously realized
New research into the earliest events occurring immediately upon infection with HIV-I shows that the virus deals a stunning blow to the immune system earlier than was previously understood. According to scientists at Duke University Medical Center, this suggests the window of opportunity for successful intervention may be only a matter of days – not weeks – after transmission, as researchers had previously believed.
A Viral Cloaking Device: Biologists show how Human Cytomegalovirus hides from the immune system
(PhysOrg.com) -- Viruses achieve their definition of success when they can thrive without killing their host. Now, biologists Pamela Bjorkman and Zhiru Yang of the California Institute of Technology have uncovered how one such virus, prevalent in humans, evolved over time to hide from the immune system.
Novel computational model describes the speed at which HIV escapes the immune response
Researchers from Utrecht University, The Netherlands, have developed a model that illustrates how HIV evades the immune system. The study, published July 18th in the open-access journal
PLoS Computational Biology, incorporates detailed interactions between a mutating virus and the immune system.
NIAID will not move forward with the PAVE 100 HIV Vaccine Trial
After soliciting and considering broad input from the scientific and HIV advocacy communities, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has determined that it will not conduct the HIV vaccine study known as PAVE 100.
UT pathologists believe they have pinpointed Achilles heel of HIV
Human Immunodeficiency Virus (HIV) researchers at The University of Texas Medical School at Houston believe they have uncovered the Achilles heel in the armor of the virus that continues to kill millions.
Researchers: Program discourages HIV transmission in Russia
(Boston)-Researchers from Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) found that sexual behavior counseling during drug addiction treatment should be considered an important component among Russian substance-dependent individuals, in order to decrease risky sexual behavior in the HIV at-risk population. This study appears in the journal
Addiction.
Mobilizing white blood cells to the lung: New discovery could lead to an improved influenza vaccine
Findings just published in the scientific journal Immunity by researchers at the Trudeau Institute shed new light on how a previously-unknown messaging mechanism within the human immune system prompts specific influenza-fighting cells to the lung airways during an infection.